Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024

20251 citationsJournal Articlehybrid Open Access

Authors

Laura L. Hammitt · Johns Hopkins University

Judith Espinoza · Johns Hopkins University

James W. Keck · Alaska Native Tribal Health Consortium

Rachel M. Hartman · Johns Hopkins University

Gilberto Alvarez-Colon · Gallup Indian Medical Center

Amanda Burrage · Tuba City Regional Health Care

Angela P. Campbell

Abstract

Nirsevimab is recommended to prevent severe respiratory syncytial virus (RSV)-associated illness among American Indian/Alaska Native (AI/AN) children <20 months of age. In a test-negative case-control analysis among 291 AI/AN children hospitalized during the 2023-2024 season, nirsevimab was 86.0% and 87.9% effective among children entering their first and second RSV seasons, respectively.

Topics & Keywords

Respiratory viral infections research Pneumonia and Respiratory Infections Viral gastroenteritis research and epidemiology

Publication Details

Published in: The Pediatric Infectious Disease Journal

Volume 44, Issue 12, pp. e464-e467

DOI: 10.1097/inf.0000000000004942

Field-Weighted Citation Impact: 1.32

Command Palette

Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024

Authors

Abstract

Topics & Keywords

Publication Details